Myeloproliferative neoplasms (MPNs) are a group of hematologic disorders encompassing myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). JAK inhibitors dominate treatment algorithms for MF and PV, while other standard-of-care regimens are phlebotomy-based or off-label uses of existing agents. This has created a competitive landscape with opportunities for the development of novel, targeted agents to treat this unique group of diseases.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in MPNs to help guide strategic and tactical commercial development decisions for market participants.